Clinical trials: Antipsychotic Agents
Treatment Resistant Schizophrenia, Obesity & Overweight
Effects of Nitraria Retusa Infusion on Clozapine-induced Metabolic Side Effects
The primary objective of the study is to assess the efficacy and tolerability of a 90-day daily supplementation with a Nitraria retusa dried crushed leaves infusion on the iatrogenic metabolic side effects induced in patients…
- Conditions
- Treatment Resistant Schizophrenia, Obesity & Overweight, Abdominal Obesity
- Trial name
- NCT07817069
- Testing
- The Nitraria retusa arm
- Where
- Tunisia
- Volunteers
- 30 people
- Sponsor
- Faculty of Medicine, Sousse
Psychotic Disorders, Schizophrenia
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after…
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT02087579
- Testing
- Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation
- Where
- 24 sites in United States, Argentina and 5 more
- Volunteers
- 305 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
The primary objective of this study was to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical…
- Trial name
- NCT00845026
- Testing
- LY2140023, aripiprazole, olanzapine
- Where
- 23 sites in United States, Germany and 2 more
- Volunteers
- 261 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Oxytocin Add on Study for Stable Schizophrenic Patients
The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with…
- Trial name
- Oxytocin (NCT00506909)
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- David Feifel
Schizophrenia Disorders
An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia
The study design is a de-escalation of current atypical AP treatment to X/T at a maintenance dose of X/T established either at 100 mg xanomeline/20 mg trospium chloride BID (total daily dose 200 mg xanomeline/40 mg trospium…
- Trial name
- NCT06924255
- Testing
- Xanomeline and Trospium Chloride
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Collaborative Neuroscience Research, LLC
Schizophrenia, Bipolar Disorder
Relative Effectiveness of Schizophrenia Therapy Study
The purpose of this study is to validate that SULT4A1-1 status stratification improves responses to atypical antipsychotics in schizophrenia and to extend these findings into bipolar disorder.
- Trial name
- REST (NCT01245348)
- Testing
- SULT4A1-1 genetic test
- Where
- United States
- Volunteers
- 1,110 people
- Sponsor
- Medco Health Solutions, Inc.
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Catatonic, Schizophrenia, Disorganized
Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone
The purpose of this study is to evaluate the efficacy, tolerability and safety of patients on long-acting Risperidone microshpheres injection.
- Conditions
- Schizophrenia, Catatonic, Schizophrenia, Disorganized, Schizophrenia, Paranoid, Schizophrenia
- Trial name
- NCT00563017
- Testing
- Long-acting Risperidone microspheres injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hospital Authority, Hong Kong
Alzheimer's Disease
CATIE-Alzheimer's Disease Trial
The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or…
- Trial name
- NCT00015548
- Testing
- Olanzapine, Quetiapine, Risperidone
- Where
- 34 sites in United States
- Volunteers
- 450 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder, Major
Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder
The primary objective is to examine changes in pre/post-augmentation healthcare costs and resource utilization in patients diagnosed with major depressive disorder (MDD) who augment their current antidepressant therapy with an…
- Trial name
- NCT01145313
- Volunteers
- 501 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia
The aim of the present study is to detect changes in the dopamine system in the brain of patients with schizophrenia, especially when pretreated with antipsychotic medication.
- Trial name
- NCT03911726
- Testing
- Single PET/MR-measurement
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia, Psychotic Disorders
The Effects of Risperidone and Olanzapine on Thinking
The goal of this research is to find ways to maximize the benefits of antipsychotic medications for cognition. Hypothesis: Risperidone and olanzapine will show greater benefits than conventional medications on assessments of…
- Trial name
- NCT00108368
- Testing
- Risperidone, Olanzapine
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Antipsychotic Induced Structural and Functional Brain Changes
Continuation of antipsychotic drug treatment for at least 12 months after remission of the first psychotic episode represents the gold clinical standard, and it is recommended by all international treatment guidelines.
- Trial name
- APIC (NCT02435095)
- Testing
- Maintenance treatment, Intermittent treatment
- Where
- 11 sites in Germany
- Volunteers
- 174 people
- Sponsor
- RWTH Aachen University
Schizophrenia
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
This 4-week study will evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide (7.5,and 15 mg and placebo, bid) treatment in outpatients with chronic schizophrenia.
- Trial name
- NCT04461119
- Testing
- Evenamide
- Where
- 14 sites in United States, India
- Volunteers
- 138 people
- Sponsor
- Newron Pharmaceuticals SPA
Schizophrenia / Schizoaffective Disorder
The Effect of Structured Medical Nutrition Therapy on Systemic Inflammation Index in Patients With Schizophrenia Receiving Antipsychotic Therapy
Patients with schizophrenia receiving long-term antipsychotic therapy are at increased risk of chronic low-grade inflammation and metabolic disturbances, which contribute to poor physical health outcomes and increased…
- Trial name
- NCT07696000
- Testing
- Modification Diet, Hospitalized Diet
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- DINA KEUMALA SARI
Major Depressive Disorder Patients
Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder
The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive…
- Trial name
- NCT01871974
- Testing
- FK949E
- Where
- 2 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Astellas Pharma Inc
Schizophrenia
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
This is an observational, non-interventional study that will include two cohorts of patients with schizophrenia who initiated maintenance treatment during a schizophrenia-related hospitalisation or during the immediate three…
- Trial name
- NCT03130465
- Where
- 67 sites in France, Germany and 2 more
- Volunteers
- 636 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Akathisia, Drug-Induced, Dyskinesia, Drug-Induced
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
This study was designed to determine if preladenant (SCH 420814, MK-3814) can reduce drug-induced involuntary movements in participants with schizophrenia or schizoaffective disorder.
- Conditions
- Akathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders
- Trial name
- NCT00686699
- Testing
- Preladenant
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Psychotic Disorders
Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication
Patients who have schizophrenia, schizoaffective disorder, a psychotic disorder, and are being treated with a medication called Risperidone Long Acting Injectable medication or another antipsychotic medication are candidates for…
- Trial name
- NCT00287027
- Testing
- Risperdal Long Acting Injectable Antipsychotic Medication
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Alliance on Mental Illness New Hampshire
Schizophrenia, Schizoaffective Disorder
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT00246259
- Testing
- Risperidone long-acting injection (LAI), Oral Antipsychotic
- Where
- 11 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Janssen-Ortho Inc., Canada